Despite the acquisition of GE Biopharma the stock performance this year is hard to quantify, it does seem that it has ran a little too far to fast and needs a healthy pullback. We assume that when the selling does start it could snowball into quite a drop as large profits are banked and sellers find it hard to offload their portfolio. We will be looking at this as a short when the indicators become more oversld
Official InvestorsHub (IHUB) Profile for TopMarketGainers.com. Since 2009, we are the #1 Source For #FREE Winning #NASDAQ & #NYSE-Listed Alerts!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.